Publicaciones en colaboración con investigadores/as de Institut d'Investigacions Biomèdiques August Pi i Sunyer (154)

2024

  1. Deep-stratification of the cardiovascular risk by ultrasound carotid artery images

    Biomedical Signal Processing and Control, Vol. 91

  2. Recommendations and quality criteria to improve the early diagnosis of primary biliary cholangitis

    Gastroenterologia y Hepatologia

  3. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

    Biomedicine and Pharmacotherapy, Vol. 170

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. ALERGODATA: Sentinel Registry of Health Outcomes in Allergic Patients Treated With Biological Therapies at Specialized Allergology Clinics in Spain

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 6, pp. 479-482

  3. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  4. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  5. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors

    Hematological Oncology, Vol. 41, Núm. 4, pp. 631-643

  6. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

  7. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

    Frontiers in Oncology, Vol. 13

  8. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  9. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO

    British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211

  10. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study

    Dermatology (Basel, Switzerland), Vol. 239, Núm. 5, pp. 685-693

  11. Role of Different Health Care Professionals in the Management of Asthma Patients: The GEMA-FORUM IV Task Force

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 214-217

  12. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

  13. Selection of Quality Indicators for the Certification of Dermato-Oncology Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. 587-605

  14. Unraveling the genetics of transformed splenic marginal zone lymphoma

    Blood Advances, Vol. 7, Núm. 14, pp. 3695-3709

  15. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

2022

  1. CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

    Blood, Vol. 140, Núm. 1, pp. 38-44

  2. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

    British Journal of Haematology, Vol. 196, Núm. 1, pp. 146-155